Instrumento Inactivo

Acciones Ariad Pharmaceuticals, Inc.

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

Ariad Pharmaceuticals : Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency	06/02/17
Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion	03/02/17
Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc.	03/02/17
Ariad Pharmaceuticals : Acquisition May Not Be in the Best Interests of ARIA Shareholders	18/01/17
Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	13/01/17

Directores	Puesto	Edad	Desde
Teresa Bitetti PSD	President	-	-
Tetsu Inada BRD	Director/Board Member	-	-
Jason E. Baranski SEC	Corporate Secretary	-	-

Administradores	Puesto	Edad	Desde
Teresa Bitetti PSD	President	-	-
Tetsu Inada BRD	Director/Board Member	-	-

Sector

	Varia. 1 de ene.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31 %	103 mil M
REGENERON PHARMACEUTICALS, INC.	+0,56 %	95,28 mil M
ARGENX SE	+1,69 %	22,15 mil M
BIONTECH SE	-17,37 %	21,02 mil M
GENMAB A/S	-9,30 %	18,15 mil M
WUXI APPTEC CO., LTD.	-41,01 %	16,74 mil M
BEIGENE, LTD.	-14,85 %	16,05 mil M
NEUROCRINE BIOSCIENCES, INC.	+3,21 %	13,68 mil M
SAREPTA THERAPEUTICS, INC.	+33,54 %	12,17 mil M